Published in Clin Pharmacol Ther on February 07, 2006
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol (2013) 1.24
Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology (2009) 1.14
ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol (2009) 1.13
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther (2008) 1.05
A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol (2011) 0.90
Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos (2008) 0.88
The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol (2008) 0.86
Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol (2009) 0.83
Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res (2009) 0.81
Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. Eur J Clin Pharmacol (2015) 0.81
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy (2013) 0.78
High-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think? Drug Saf Case Rep (2015) 0.75
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J (2005) 1.71
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18
Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08
Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04
Sustained neuronal activity generated by glial plasticity. J Neurosci (2011) 1.03
The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos (2002) 1.01
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS (2008) 0.99
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos (2004) 0.96
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol (2006) 0.95
Literature mining on pharmacokinetics numerical data: a feasibility study. J Biomed Inform (2009) 0.93
In vivo real-time 3-D intracardiac echo using PMUT arrays. IEEE Trans Ultrason Ferroelectr Freq Control (2014) 0.92
Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos (2008) 0.91
A general linear model for MEG beamformer imaging. Neuroimage (2004) 0.91
Molecular analysis of thymoma. PLoS One (2012) 0.90
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos (2012) 0.89
Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest (2007) 0.89
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol (2012) 0.88
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos (2005) 0.88
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos (2002) 0.88
Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol (2005) 0.88
Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Invest (2012) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87
Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opin Drug Saf (2006) 0.86
A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn (2009) 0.86
Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model (2013) 0.86
Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans. J Neurosci (2013) 0.85
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos (2005) 0.85
Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control (2007) 0.85
Insulin sensitivity is preserved despite disrupted endothelial function. Am J Physiol Endocrinol Metab (2006) 0.85
Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit (2008) 0.84
Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest (2009) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. J Alzheimers Dis (2012) 0.83
Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol (2007) 0.83
Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos (2013) 0.82
Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther (2008) 0.82
Primary and secondary somatosensory cortex responses to anticipation and pain: a magnetoencephalography study. Eur J Neurosci (2011) 0.82
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. Eur J Clin Pharmacol (2012) 0.82
A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics (2008) 0.82
A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population pharmacokinetics (PK) models. J Biopharm Stat (2009) 0.81
Irreversible enzyme inhibition kinetics and drug-drug interactions. Methods Mol Biol (2014) 0.81
The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine. Drug Metab Dispos (2013) 0.81
The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos (2004) 0.81
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos (2013) 0.80
A multimodal perspective on the composition of cortical oscillations. Front Hum Neurosci (2013) 0.80
Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats. Drug Metab Dispos (2010) 0.79